Thanks Ian, that is interesting. One thing about the safety of FTY720 that I've been wondering is whether the deaths in the phase 3 trial were in the high dose or low dose arm. If they were in the high dose arm, then there is still hope that the safety profile of the low dose will be ok.
One quote I found interesting,
Only 5 percent of all MS compounds that entered clinical trials in 1995 or later won FDA approval—that's significantly less than the industry average of 12 percent.